Hochtief’s DAX Promotion Unleashes a 10% Sell-Off as Thin Free Float and Profit-Taking Overshadow a €79 Billion Order Book

The stock’s first week in Germany’s blue-chip index has been anything but celebratory. Since its DAX debut on June 22, Hochtief shares have shed around 10% of their value, closing Friday at €497.60 — a daily drop of 2.72%. The sell-off follows a familiar pattern: investors who piled in ahead of the index change are now cashing out, while passive funds that were forced to buy the stock at the reconstitution date have moved on, leaving the shares without a structural bid.

A tight free float is magnifying the move. Spain’s ACS, the parent company, holds roughly 80% of Hochtief’s equity, leaving barely a fifth of the stock available for public trading. With a market capitalisation of about €38 billion, even modest volumes can trigger outsized price swings. The same mechanism that propelled the shares into the DAX is now amplifying the retreat.

Yet the sell-off sits uncomfortably alongside the company’s operational momentum. The order book stood at a record €79.3 billion at the end of March, up from around €70 billion a year earlier. Demand for data centres serving artificial intelligence, rising defence budgets, and large-scale infrastructure programmes in the United States drove the inflow — fully 60% of new contracts in the first quarter came from these high-growth areas. The management expects 2026 operating net profit to reach around €1 billion, a potential increase of up to 30% from the prior year.

Should investors sell immediately? Or is it worth buying Hochtief?

To secure that future, Hochtief is also moving into nuclear energy. In partnership with US-based Amentum, the builder plans to construct small modular reactors (SMRs) for Rolls-Royce, with initial projects in the UK and the Czech Republic. The reactors would be prefabricated in factories, slashing construction times and costs. The European Commission is backing the trend, and the first units could come online in the early 2030s. Biopharma projects and the broader energy transition are also in the pipeline.

Despite the recent slide, the longer-term chart remains striking. The stock has tripled over the past twelve months from a 52-week low of €162.10 and still trades about 33% above its 200-day moving average. Since the start of the year the gain is roughly 47%. But the rapid ascent has drawn scepticism from analysts, who see limited upside from here. The average price target among eight experts is €463.93 — well below the current level — with forecasts ranging from €259 to €605. The consensus is neutral, implying that the structural demand from DAX-tracking funds has not settled the valuation debate.

The technical overhang from the index reconstitution typically fades within a few weeks. The next catalyst comes in July, when Hochtief reports second-quarter results. A strong operational showing could refocus attention on the underlying business and provide support. In the meantime, the 50-day moving average near €489 is expected to act as a floor, though with only one in five shares freely tradeable, the ride is likely to stay volatile.